Non-Current Assets

Other Non-Current Assets

Gilead Sciences Other Non-Current Assets decreased by 6.0% to $4.55B in Q1 2026 compared to the prior quarter.

Analysis

StatementBalance Sheet Statement
SectionNon-Current Assets
CategoryOther
SignalContext dependent
VolatilityStable
First reportedQ4 2025
Last reportedQ1 2026

How to read this metric

Significant changes may indicate shifts in accounting estimates, tax positions, or non-core asset holdings.

Detailed definition

This category includes long-term assets that do not fit into specific classifications like PP&E or intangibles, such as...

Peer comparison

Standard line item in most balance sheets, often labeled 'Other non-current assets'.

Metric ID: non_current_assets_other_assets_noncurrent

Historical Data

2 periods
 Q4 '25Q1 '26
Value$4.85B$4.55B
QoQ Change—-6.0%
Range$4.55B – $4.85B

Other Non-Current Assets at Other Companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMYView metric
Merck & Co. logo
Merck & Co.MRKView metric
Amgen logo
AmgenAMGNView metric
AbbVie logo
AbbVieABBVView metric
Pfizer logo
PfizerPFEView metric
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGNView metric

Frequently Asked Questions

What is Gilead Sciences's other non-current assets?
Gilead Sciences (GILD) reported other non-current assets of $4.55B in Q1 2026.
What does other non-current assets mean?
Miscellaneous long-term assets that do not fall into standard categories.